Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Market just crazy right now, longs are still green from last month, no worries.
Let it rip
Look at Morin’s a the company they bought, huge lot cleared next to it.
Large float moves slow but once we get rolling look out. GLTA
For sure, nice volume and nice close.
SWEET
With Morgan and piper upgrades hopefully we can see some new 52-week highs. GLTA
I agree, hopefully some surprise news soon. They are doing a lot of hiring on their website hopefully a good sign. 1/19 just around the corner.
The CC was positive, and January keeps getting closer, IMO, we should b moving up soon.
No doubt, power hour could be interesting.
Neutral to good.
Yes sir, after the bell today.
If the ER is good with some positive guidance IMO, we could definitely see a climb.
Offering expected
Been on since 1.90’S, love watching shorties burn. BOOM
NICE, news out
I see that gipper, looks good, let’s squeeze a little more
Churn baby churn
For sure, they can move markets, good upgrade.
Just JPM upgrade, the went from bearish to bullish. Said trials have a better chance to be positive than negative.
This looks real similar to the old APS plays
YES SIR
Hopefully good news at the conference today. GLTA
LOL
About to find out
The dip before the rip
Good info senderos
IDK, but no news no reason for the drop.
Low floater could fly tomorrow. GLTA
CEO bought 100K shares
Just another day in biotech, EXEL did the exact same thing then it shot over $10 and now over $20, I’m still long and strong, buying the dips, no bad news here. GLTA
LETS ROLL
It’s time for this tootsie roll to get lit up.
I agree, but it was obviously big boys that scooped up almost 35-mill shares in 3-days, they always buy @ a discount.
GAITHERSBURG, Md., April 11, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases, today announced that it has priced an underwritten public offering of 30,303,050 shares of common stock at a price to the public of $1.65 per share for gross proceeds of $50 million, before deducting the underwriting discounts and offering expenses. In connection with this offering, Novavax has granted the underwriters a 30-day option to purchase up to an additional 4,545,457 shares of its common stock. If the underwriters exercise this option in full, Novavax will have sold 34,848,507 shares of its common